Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 325

1.

[Novel therapies for acute myeloid leukemia based on genomic aberrations].

Umezawa Y, Kawamata N.

Rinsho Ketsueki. 2019;60(6):594-599. doi: 10.11406/rinketsu.60.594. Japanese.

PMID:
31281150
2.

Meningeal carcinomatosis from bladder cancer: A case report and review of the literature.

Umezawa Y, Shirotake S, Kaneko G, Nishimoto K, Okada Y, Uchino A, Yasuda M, Oyama M.

Mol Clin Oncol. 2019 May;10(5):506-510. doi: 10.3892/mco.2019.1820. Epub 2019 Mar 5.

3.

Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.

Akiyama H, Umezawa Y, Ishida S, Okada K, Nogami A, Miura O.

Cancer Lett. 2019 Jul 1;453:84-94. doi: 10.1016/j.canlet.2019.03.046. Epub 2019 Apr 1.

PMID:
30946869
4.

Relationship between the Degrees of Itch and Serum Lipocalin-2 Levels in Patients with Psoriasis.

Aizawa N, Ishiuji Y, Tominaga M, Sakata S, Takahashi N, Yanaba K, Umezawa Y, Asahina A, Kimura U, Suga Y, Takamori K, Nakagawa H.

J Immunol Res. 2019 Jan 21;2019:8171373. doi: 10.1155/2019/8171373. eCollection 2019.

5.

Interstitial Pneumonia in Psoriasis.

Kawamoto H, Hara H, Minagawa S, Numata T, Araya J, Kaneko Y, Umezawa Y, Asahina A, Nakagawa H, Kuwano K.

Mayo Clin Proc Innov Qual Outcomes. 2018 Sep 20;2(4):370-377. doi: 10.1016/j.mayocpiqo.2018.07.006. eCollection 2018 Dec.

6.

Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway.

Nogami A, Okada K, Ishida S, Akiyama H, Umezawa Y, Miura O.

Transl Oncol. 2019 Feb;12(2):336-349. doi: 10.1016/j.tranon.2018.11.001. Epub 2018 Nov 22.

7.

Dynamics of Sulfate-Reducing Bacteria Community Structure in Surface Sediment of a Seasonally Hypoxic Enclosed Bay.

Mori F, Umezawa Y, Kondo R, Wada M.

Microbes Environ. 2018 Dec 28;33(4):378-384. doi: 10.1264/jsme2.ME18092. Epub 2018 Nov 17.

8.

Diurnal and seasonal variation of particle and dissolved organic matter release by the coral Acropora tenuis.

Kurihara H, Ikeda N, Umezawa Y.

PeerJ. 2018 Nov 7;6:e5728. doi: 10.7717/peerj.5728. eCollection 2018.

9.

Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.

Umezawa Y, Torisu-Itakura H, Morisaki Y, ElMaraghy H, Nakajo K, Akashi N, Saeki H; Japanese Ixekizumab Study Group.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):568-576. doi: 10.1111/jdv.15292. Epub 2018 Nov 13.

10.

Serum KL-6 levels in Japanese patients with psoriasis treated with secukinumab.

Kurita M, Kikuchi S, Umezawa Y, Asahina A, Nakagawa H, Yanaba K.

J Dermatol. 2019 Apr;46(4):e115-e116. doi: 10.1111/1346-8138.14630. Epub 2018 Sep 11. No abstract available.

PMID:
30204267
11.

Evaluation of epicardial adipose tissue volume and coronary artery calcification in Japanese patients with psoriasis vulgaris.

Momose M, Asahina A, Fukuda T, Sakuma T, Umezawa Y, Nakagawa H.

J Dermatol. 2018 Nov;45(11):1349-1352. doi: 10.1111/1346-8138.14618. Epub 2018 Aug 27.

PMID:
30152023
12.

Anti-SAE Antibody-Positive Dermatomyositis in a Japanese Patient: A Case Report and Review of the Literature.

Matsuo H, Yanaba K, Umezawa Y, Nakagawa H, Muro Y.

J Clin Rheumatol. 2018 Aug 2. doi: 10.1097/RHU.0000000000000683. [Epub ahead of print] No abstract available.

PMID:
30074913
13.

Usefulness of dual-energy computed tomography for the evaluation of psoriatic arthritis accompanied by knee osteoarthritis.

Umezawa Y, Yanaba K, Asahina A, Nakagawa H, Fukuda T, Fukuda K.

J Dermatol. 2019 Jan;46(1):e30-e32. doi: 10.1111/1346-8138.14530. Epub 2018 Jul 5. No abstract available.

PMID:
29974970
14.

Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2.

Ishida S, Akiyama H, Umezawa Y, Okada K, Nogami A, Oshikawa G, Nagao T, Miura O.

Oncotarget. 2018 Jun 1;9(42):26834-26851. doi: 10.18632/oncotarget.25515. eCollection 2018 Jun 1.

15.

Effects of bottom-water hypoxia on sediment bacterial community composition in a seasonally hypoxic enclosed bay (Omura Bay, West Kyushu, Japan).

Mori F, Umezawa Y, Kondo R, Wada M.

FEMS Microbiol Ecol. 2018 May 1;94(5). doi: 10.1093/femsec/fiy053.

PMID:
29579183
16.

Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases.

Ishiuji Y, Umezawa Y, Asahina A, Fukuta H, Aizawa N, Yanaba K, Nakagawa H.

J Dermatol. 2018 Jun;45(6):732-734. doi: 10.1111/1346-8138.14295. Epub 2018 Mar 22.

PMID:
29569296
17.

FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.

Okada K, Nogami A, Ishida S, Akiyama H, Chen C, Umezawa Y, Miura O.

Oncotarget. 2017 Dec 4;9(10):8870-8886. doi: 10.18632/oncotarget.22926. eCollection 2018 Feb 6.

18.

Case of psoriatic patient who maintains long-term remission after anti-hepatitis C virus agents and ustekinumab treatment.

Kikuchi S, Umezawa Y, Chihara M, Asahina A, Nakagawa H.

J Dermatol. 2018 Mar;45(3):e59-e60. doi: 10.1111/1346-8138.14229. Epub 2018 Jan 31. No abstract available.

PMID:
29388245
19.

New onset of psoriasis during nivolumab treatment for lung cancer.

Chujo S, Asahina A, Itoh Y, Kobayashi K, Sueki H, Ishiji T, Umezawa Y, Nakagawa H.

J Dermatol. 2018 Mar;45(3):e55-e56. doi: 10.1111/1346-8138.14167. Epub 2017 Dec 4. No abstract available.

PMID:
29205470
20.

Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.

Momose M, Asahina A, Umezawa Y, Nakagawa H.

J Dermatol. 2018 Mar;45(3):318-321. doi: 10.1111/1346-8138.14145. Epub 2017 Nov 30.

PMID:
29194723
21.

Highly heterogeneous diazotroph communities in the Kuroshio Current and the Tokara Strait, Japan.

Cheung S, Suzuki K, Saito H, Umezawa Y, Xia X, Liu H.

PLoS One. 2017 Oct 23;12(10):e0186875. doi: 10.1371/journal.pone.0186875. eCollection 2017.

22.

The competitive nature of signal transducer and activator of transcription complex formation drives phenotype switching of T cells.

Sadreev II, Chen MZQ, Umezawa Y, Biktashev VN, Kemper C, Salakhieva DV, Welsh GI, Kotov NV.

Immunology. 2018 Apr;153(4):488-501. doi: 10.1111/imm.12851. Epub 2017 Nov 22.

23.

Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1).

Umezawa Y, Akiyama H, Okada K, Ishida S, Nogami A, Oshikawa G, Kurosu T, Miura O.

J Biol Chem. 2017 Dec 1;292(48):19639-19655. doi: 10.1074/jbc.M117.779603. Epub 2017 Oct 3.

24.

Usefulness of dual-energy computed tomography for the evaluation of early-stage psoriatic arthritis only accompanied by nail psoriasis.

Asahina A, Fukuda T, Ishiuji Y, Yaginuma A, Yanaba K, Umezawa Y, Nakagawa H.

J Dermatol. 2017 Dec;44(12):e326-e327. doi: 10.1111/1346-8138.14008. Epub 2017 Aug 24. No abstract available.

PMID:
28836684
25.

New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study.

Asahina A, Umezawa Y, Momose M, Honda H, Yanaba K, Nakagawa H.

J Dermatol. 2017 Dec;44(12):1380-1384. doi: 10.1111/1346-8138.13987. Epub 2017 Aug 3.

PMID:
28771778
26.

Dual energy CT iodine map for delineating inflammation of inflammatory arthritis.

Fukuda T, Umezawa Y, Asahina A, Nakagawa H, Furuya K, Fukuda K.

Eur Radiol. 2017 Dec;27(12):5034-5040. doi: 10.1007/s00330-017-4931-8. Epub 2017 Jul 3.

PMID:
28674965
27.

Superiority of magnetic resonance imaging over conventional radiography in the early diagnosis of psoriatic arthritis.

Hayashi M, Yanaba K, Umezawa Y, Asahina A, Nakagawa H.

J Dermatol. 2017 Oct;44(10):e232-e233. doi: 10.1111/1346-8138.13918. Epub 2017 May 30. No abstract available.

PMID:
28556938
28.

Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.

Asahina A, Kubo N, Umezawa Y, Honda H, Yanaba K, Nakagawa H.

J Dermatol. 2017 Oct;44(10):1112-1121. doi: 10.1111/1346-8138.13875. Epub 2017 May 11.

PMID:
28493493
29.

Switching of biologics in psoriasis: Reasons and results.

Honda H, Umezawa Y, Kikuchi S, Yanaba K, Fukuchi O, Ito T, Nobeyama Y, Asahina A, Nakagawa H.

J Dermatol. 2017 Sep;44(9):1015-1019. doi: 10.1111/1346-8138.13860. Epub 2017 May 10.

PMID:
28488283
30.

Silencing of homeobox A5 gene in the stratum corneum of psoriasis.

Nobeyama Y, Umezawa Y, Nakagawa H.

Exp Dermatol. 2017 Nov;26(11):1068-1074. doi: 10.1111/exd.13377. Epub 2017 Aug 15.

PMID:
28482119
31.

Evidence of chronic anthropogenic nutrient within coastal lagoon reefs adjacent to urban and tourism centers, Kenya: A stable isotope approach.

Mwaura J, Umezawa Y, Nakamura T, Kamau J.

Mar Pollut Bull. 2017 Jun 30;119(2):74-86. doi: 10.1016/j.marpolbul.2017.04.028. Epub 2017 Apr 28.

PMID:
28457557
32.

Biologic treatments for elderly patients with psoriasis.

Momose M, Asahina A, Hayashi M, Yanaba K, Umezawa Y, Nakagawa H.

J Dermatol. 2017 Sep;44(9):1020-1023. doi: 10.1111/1346-8138.13853. Epub 2017 Apr 25.

PMID:
28439956
33.

Impact of anti-tumor necrosis factor-α agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis.

Hayashi M, Yanaba K, Umezawa Y, Asahina A, Nakagawa H.

J Dermatol. 2017 Sep;44(9):1063-1066. doi: 10.1111/1346-8138.13837. Epub 2017 Mar 31.

PMID:
28370220
34.

Relapsing polychondritis associated with psoriasis vulgaris successfully treated with adalimumab: A case report with published work review.

Matsuo H, Asahina A, Fukuda T, Umezawa Y, Nakagawa H.

J Dermatol. 2017 Jul;44(7):826-829. doi: 10.1111/1346-8138.13796. Epub 2017 Mar 7. Review.

PMID:
28266051
35.

Corrigendum to "IL-10-producing regulatory B cells are decreased in patients with psoriasis" [J. Dermatol. Sci. 81 (2016) 93-100].

Hayashi M, Yanaba K, Umezawa Y, Yoshihara Y, Kikuchi S, Ishiuji Y, Saeki H, Nakagawa H.

J Dermatol Sci. 2017 Apr;86(1):79. doi: 10.1016/j.jdermsci.2017.01.010. Epub 2017 Feb 10. No abstract available.

PMID:
28209293
36.

Initial Experience of Using Dual-Energy CT with an Iodine Overlay Image for Hand Psoriatic Arthritis: Comparison Study with Contrast-enhanced MR Imaging.

Fukuda T, Umezawa Y, Tojo S, Yonenaga T, Asahina A, Nakagawa H, Fukuda K.

Radiology. 2017 Jul;284(1):134-142. doi: 10.1148/radiol.2016161671. Epub 2017 Jan 3.

PMID:
28045646
37.

Successful treatment of ustekinumab in a psoriasis patient with human T-cell leukemia/lymphotropic virus type 1 infection.

Kazama M, Umezawa Y, Itoh M, Nobeyama Y, Ito T, Kikuchi S, Yanaba K, Asahina A, Nakagawa H, Ogasawara Y.

J Dermatol. 2017 Nov;44(11):1334-1335. doi: 10.1111/1346-8138.13678. Epub 2016 Nov 18. No abstract available.

PMID:
27864824
38.

Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis.

Umezawa Y, Nakagawa H, Niiro H, Ootaki K; Japanese Brodalumab Study Group.

J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1957-1960. doi: 10.1111/jdv.13785. Epub 2016 Jun 29.

PMID:
27358210
39.

A genetically encoded bioluminescent indicator for illuminating proinflammatory cytokines.

Kim SB, Ozawa T, Umezawa Y.

MethodsX. 2016 Jul 7;3:483-9. doi: 10.1016/j.mex.2016.06.001. eCollection 2016.

40.

Multicolor Imaging of Bifacial Activities of Estrogens.

Kim SB, Umezawa Y.

Methods Mol Biol. 2016;1461:153-63. doi: 10.1007/978-1-4939-3813-1_12.

PMID:
27424902
41.

Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells.

Umezawa Y, Kurosu T, Akiyama H, Wu N, Nogami A, Nagao T, Miura O.

Oncotarget. 2016 Jul 12;7(28):44448-44461. doi: 10.18632/oncotarget.9844.

42.

Acquired hemophilia A and fulminant diabetes mellitus possibly caused by adalimumab in a patient with psoriatic arthritis.

Yamaguchi T, Itoh M, Umezawa Y, Asahina A, Hanabusa H, Nakagawa H.

J Dermatol. 2017 Mar;44(3):e3-e4. doi: 10.1111/1346-8138.13468. Epub 2016 May 21. No abstract available.

PMID:
27206322
43.

Less-invasive analysis of DNA methylation using psoriatic scales.

Nobeyama Y, Umezawa Y, Nakagawa H.

J Dermatol Sci. 2016 Jul;83(1):70-3. doi: 10.1016/j.jdermsci.2016.03.013. Epub 2016 Apr 16. No abstract available.

PMID:
27138624
44.

Kinetic regulation of multi-ligand binding proteins.

Salakhieva DV, Sadreev II, Chen MZ, Umezawa Y, Evstifeev AI, Welsh GI, Kotov NV.

BMC Syst Biol. 2016 Apr 18;10:32. doi: 10.1186/s12918-016-0277-0.

45.

Phosphorus as a driver of nitrogen limitation and sustained eutrophic conditions in Bolinao and Anda, Philippines, a mariculture-impacted tropical coastal area.

Ferrera CM, Watanabe A, Miyajima T, San Diego-McGlone ML, Morimoto N, Umezawa Y, Herrera E, Tsuchiya T, Yoshikai M, Nadaoka K.

Mar Pollut Bull. 2016 Apr 15;105(1):237-48. doi: 10.1016/j.marpolbul.2016.02.025. Epub 2016 Feb 28.

PMID:
26936120
46.

Recurrent neutrophilic dermatosis of the face: A report of two cases and review of the published work.

Maki T, Yanaba K, Ishiuji Y, Umezawa Y, Asahina A, Nakagawa H.

J Dermatol. 2016 Jul;43(7):811-4. doi: 10.1111/1346-8138.13270. Epub 2016 Jan 27. Review.

PMID:
26813868
47.

Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.

Asahina A, Umezawa Y, Yanaba K, Nakagawa H.

J Dermatol. 2016 Jul;43(7):779-84. doi: 10.1111/1346-8138.13213. Epub 2015 Dec 24.

PMID:
26704718
48.

Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment.

Kikuchi S, Umezawa Y, Hayashi M, Yanaba K, Fukuchi O, Ito T, Asahina A, Saeki H, Nakagawa H.

J Dermatol. 2016 Jun;43(6):712-3. doi: 10.1111/1346-8138.13250. Epub 2015 Dec 24. No abstract available.

PMID:
26703791
49.

Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.

Yanaba K, Umezawa Y, Honda H, Sato R, Chiba M, Kikuchi S, Asahina A, Nakagawa H.

J Dermatol. 2016 Apr;43(4):443-4. doi: 10.1111/1346-8138.13215. Epub 2015 Dec 12. No abstract available.

PMID:
26662275
50.

IL-10-producing regulatory B cells are decreased in patients with psoriasis.

Hayashi M, Yanaba K, Umezawa Y, Yoshihara Y, Kikuchi S, Ishiuji Y, Saeki H, Nakagawa H.

J Dermatol Sci. 2016 Feb;81(2):93-100. doi: 10.1016/j.jdermsci.2015.11.003. Epub 2015 Nov 14. Erratum in: J Dermatol Sci. 2017 Apr;86(1):79.

PMID:
26614745

Supplemental Content

Loading ...
Support Center